US Supreme Court rejected pharma industry challenge to Medicare drug pricing law

The U.S. Supreme Court declined to hear a pharmaceutical industry challenge against the Biden-era Medicare drug price negotiation programme, leaving in place lower court rulings that upheld the policy under the Inflation Reduction Act.

The decision affected legal appeals brought by major drugmakers including Novo Nordisk, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Novartis and Boehringer Ingelheim.

The programme, introduced under former President Joe Biden’s Inflation Reduction Act, allows Medicare to negotiate prices directly with manufacturers for selected high-cost medicines. Companies that refuse to participate could face substantial financial penalties or lose access to Medicare and Medicaid markets.

Drugmakers argued the policy effectively imposed government-controlled pricing and threatened pharmaceutical innovation. The industry also claimed the law violated constitutional protections relating to free speech, due process and property rights.

Despite the legal challenges, negotiated prices on an initial group of 10 drugs had already taken effect this year. The Trump administration continued defending the programme, positioning it as part of broader efforts to reduce prescription drug costs for Medicare beneficiaries.

The ruling reinforced growing regulatory pressure on pharmaceutical pricing in the United States, an issue investors continue monitoring closely as policymakers seek to curb healthcare spending while balancing concerns around innovation and long-term drug development incentives.